Completed PHASE2 INTERVENTIONAL 3-arm NCT02255604

Effect of Intralymphatic Immunotherapy

Effect of Intralymphatic Immunotherapy at Basophil Response and Plasmacell Kinetic in Patients With Allergic Rhinitis.

Sponsor: University of Aarhus

Conditions Allergy Immune Tolerance Injection Site Discomfort

Interventions 0.1 ml Isoton saline Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml. alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.

Updated 10 times since 2017 Last updated: Apr 27, 2021 Started: Aug 31, 2013 Primary completion: Sep 30, 2015 Completion: Feb 1, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Allergy and Immune Tolerance and is currently completed. University of Aarhus leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jun 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Apr 2021 — Jun 2021 [monthly]

Completed PHASE2
Jan 2021 — Apr 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2017 — Dec 2017 [monthly]

Unknown Status PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Aarhus

Data source: University of Aarhus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aarhus, Denmark